Leukemia, T-Cell
Showing 1 - 25 of >10,000
Lymphoma, B-Cell, Leukemia, B-cell, Leukemia, T-Cell Trial in Cangzhou (CAR-T)
Recruiting
- Lymphoma, B-Cell
- +3 more
- CAR-T
-
Cangzhou, Hebei, ChinaCangzhou People's Hospital
Nov 9, 2022
T-cell Lymphoma, T-cell Leukemia Trial in Indianapolis (CD4CAR)
Recruiting
- T-cell Lymphoma
- T-cell Leukemia
- CD4CAR
-
Indianapolis, IndianaIndiana University Melvin and Bren Simon Comprehensive Cancer Ce
Dec 16, 2022
T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma Trial in Saint Louis (WU-CART-007)
Not yet recruiting
- T-Cell Non-Hodgkin Lymphoma
- +14 more
- WU-CART-007
-
Saint Louis, MissouriWashington University School of Medicine
Jan 17, 2023
Leukemia, T Cell Trial in Beijing (CD7 CART)
Recruiting
- Leukemia, T Cell
- CD7 CART
-
Beijing, Hebei, ChinaHe bei Yan da Lu dao pei Hospital
May 24, 2022
Adult T-Cell Lymphoma/Leukemia, Sezary Syndrome, Mycosis Fungoides Trial run by the NCI (Recombinant human Interleukin-15
Completed
- Adult T-Cell Lymphoma/Leukemia
- +2 more
- Recombinant human Interleukin-15 (rhIL-15)
- Mogamulizumab
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Dec 9, 2022
T Cell Lymphoma, T-cell Leukemia Trial in Beijing (chimeric antigen receptor T cell treatment)
Recruiting
- T Cell Lymphoma
- T-cell Leukemia
- chimeric antigen receptor T cell treatment
-
Beijing, Beijing, ChinaBeijing Boren Hospital
Aug 12, 2022
T Lymphoblastic Leukemia/Lymphoma Trial in Hangzhou (Chidamide)
Recruiting
- T Lymphoblastic Leukemia/Lymphoma
-
Hangzhou, Zhejiang, ChinaThe First Hospital of Zhejiang Medical Colleage Zhejiang Univers
Aug 7, 2023
Relapsed/Refractory Large Granular T Lymphocytic Leukemia Trial in Zhoukou, Tianjin (Linperlisib)
Not yet recruiting
- Relapsed/Refractory Large Granular T Lymphocytic Leukemia
-
Zhoukou, Henan, China
- +1 more
Dec 22, 2022
Lymphoma, Adult T-Cell Leukemia/Lymphoma, Lymphatic Diseases Trial in Hollywood, Boston, Chapel Hill (Brentuximab Vedotin, CHEP)
Active, not recruiting
- Lymphoma
- +2 more
- Brentuximab Vedotin
- CHEP
-
Hollywood, Florida
- +3 more
Nov 30, 2022
T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Trial (CD7-CART01)
Not yet recruiting
- T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- CD7-CART01
- (no location specified)
Sep 26, 2023
Extranodal NK T Cell Lymphoma, NK-Cell Leukemia Trial in Xuzhou (Anti-CD56 CAR T)
Recruiting
- Extranodal NK T Cell Lymphoma
- NK-Cell Leukemia
- Anti-CD56 CAR T
-
Xuzhou, Jiangsu, ChinaThe Affiliated Hospital of Xuzhou Medical University
Jul 10, 2023
T-cell Leukemia/Lymphoma, Refractory T Lymphoblastic Leukemia/Lymphoma, Relapse/Recurrence Trial in Beijing (chimeric antigen
Recruiting
- T-cell Leukemia/Lymphoma
- +2 more
- chimeric antigen receptor T cell treatment
-
Beijing, Beijing, ChinaBeijing Boren Hospital
Jul 31, 2022
Refractory Leukemia, Relapsed Leukemia, Acute Myelogenous Leukemia Trial in Miami (STING-Dependent Activators (STAVs) Loaded
Not yet recruiting
- Refractory Leukemia
- +4 more
- STING-Dependent Activators (STAVs) Loaded Autologous Leukemic Cells
- Dendritic Cell Vaccine
-
Miami, FloridaUniversity of Miami
Jan 23, 2023
B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- +2 more
- CD19/CD22-bispecific CAR-T cells
-
Beijing, Beijing, ChinaLiang Wang
Oct 7, 2023
Acute Myeloid Leukemia (AML), B-cell Non-Hodgkin's Lymphoma (B-NHL), Multiple Myeloma (MM) Trial in Shanghai (Autologous CAR-T
Recruiting
- Acute Myeloid Leukemia (AML)
- +4 more
- Autologous CAR-T cells
- +2 more
-
Shanghai, Shanghai, ChinaShanghai Pudong Hospital, Fudan University Affiliated Pudong Med
Aug 22, 2022
T-Cell Acute Lymphocytic Leukemia Trial in Langfang (CD7 CAR-T)
Recruiting
- T-Cell Acute Lymphocytic Leukemia
- CD7 CAR-T
-
Langfang, Hebei, ChinaHebei Yanda Hospital
Jun 26, 2023
Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Adult T-Cell
Recruiting
- Recurrent Adult T-Cell Leukemia/Lymphoma
- +3 more
- Cyclophosphamide
- +5 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Nov 18, 2022
Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti Tim-3/CD123 CAR-T cell therapy)
Recruiting
- Acute Myeloid Leukemia Refractory
- Acute Myeloid Leukemia, in Relapse
- anti Tim-3/CD123 CAR-T cell therapy
-
Xuzhou, Jiangsu, ChinaKailin Xu
Nov 4, 2023
Leukemia, Myeloid, Acute, Leukemia, B-cell, Leukemia, T Cell Trial in Monza (Sport Therapy)
Recruiting
- Leukemia, Myeloid, Acute
- +7 more
- Sport Therapy
-
Monza, MB, ItalyMaria Letizia Verga Center, Pediatric Clinic, University of Mila
Oct 24, 2022
B-Cell Non Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia Trial in Hanoi (anti-CD19 CAR T-cells)
Recruiting
- B-Cell Non Hodgkin Lymphoma
- B-Cell Acute Lymphoblastic Leukemia
- anti-CD19 CAR T-cells
-
Hanoi, VietnamVinmec Research Institute of Stem Cell and Gene Technology
Sep 5, 2023
Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia Trial in Philadelphia (BEAM-201)
Recruiting
- Lymphoblastic Lymphoma
- +2 more
- BEAM-201
-
Philadelphia, PennsylvaniaChildren's Hospital of Philadelphia
Jun 2, 2023
T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia Trial in United States (Optional Blood Sample, Optional Nail
Recruiting
- T-cell Lymphoma
- +30 more
- Optional Blood Sample
- Optional Nail Sample
-
Duarte, California
- +25 more
Jul 28, 2023
B-cell Acute Lymphoblastic Leukemia Trial (CD19-CAR_Lenti_ALLO)
Not yet recruiting
- B-cell Acute Lymphoblastic Leukemia
- (no location specified)
Oct 10, 2023
Adult T-cell Leukemia/Lymphoma, Extranodal NK-/T-cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma Trial run by
Not yet recruiting
- Adult T-cell Leukemia/Lymphoma
- +4 more
- CC-486 (5-azacitidine)
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 17, 2022
Plasma Cell Leukemia Trial in Tianjin (anti-BCMA CAR-T, VRD-based regimen)
Recruiting
- Plasma Cell Leukemia
- anti-BCMA CAR-T
- VRD-based regimen
-
Tianjin, ChinaInstitute of Hematology and Blood Diseases Hospital Chinese Acad
Aug 4, 2023